Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OMEPRAZOLE AND SODIUM BICARBONATE vs PROBALAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Omeprazole is a proton pump inhibitor that suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells. Sodium bicarbonate is an antacid that neutralizes gastric acid.
Inhibits xanthine oxidase, reducing uric acid production.
Duodenal ulcer,Gastric ulcer,Gastroesophageal reflux disease (GERD),Erosive esophagitis,Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome),Helicobacter pylori eradication (in combination with antibiotics),Prevention of upper gastrointestinal bleeding in critically ill patients (off-label),Treatment of dyspepsia (off-label)
Gout,Hyperuricemia,Prevention of tumor lysis syndrome
Omeprazole 20 mg plus sodium bicarbonate 1100 mg orally once daily before a meal; for gastroesophageal reflux disease, dose may be increased to 40 mg orally once daily for 4-8 weeks.
500 mg orally once daily.
Terminal elimination half-life of omeprazole is approximately 0.5-1 hour. However, the pharmacodynamic effect (gastric acid suppression) lasts longer due to accumulation in parietal cells. Half-life does not correlate with duration of acid suppression.
Terminal elimination half-life is 6-8 hours in patients with normal renal function; prolonged to 20-40 hours in severe renal impairment (Cr Cl <30 m L/min) requiring dose adjustment.
Omeprazole is extensively metabolized in the liver by cytochrome P450 (CYP) enzymes, primarily CYP2C19 and CYP3A4, to inactive metabolites. Sodium bicarbonate is not metabolized; it dissociates into sodium and bicarbonate ions.
Primarily hepatic via CYP450; produces active metabolites.
Omeprazole is primarily metabolized by CYP2C19 and CYP3A4; metabolites are excreted renally (~77% as metabolites) and fecally (~20% as metabolites). Urinary excretion of unchanged omeprazole is negligible (<1%). Sodium bicarbonate is excreted renally as bicarbonate and carbon dioxide.
Primarily renal excretion of unchanged drug (60-70%) via glomerular filtration and tubular secretion; biliary/fecal excretion accounts for 15-25% with the remainder as metabolites.
Omeprazole is 95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
90-95% bound primarily to albumin and alpha-1-acid glycoprotein.
Apparent volume of distribution is approximately 0.3-0.5 L/kg, suggesting distribution into total body water. The active form accumulates in parietal cell canaliculi.
0.15-0.25 L/kg; reflects distribution mainly into extracellular fluid with limited tissue penetration.
Oral bioavailability is approximately 30-40% after a single dose, increasing to 60-70% with repeated administration due to decreased first-pass metabolism. Bioavailability is not affected by food but is enhanced by the sodium bicarbonate component, which protects omeprazole from acid degradation.
Oral: 75-85% (first-pass metabolism reduces absolute bioavailability); Intravenous: 100%.
No dosage adjustment required for mild to moderate renal impairment; for severe renal impairment (GFR <30 m L/min), use with caution and monitor for sodium overload.
Cr Cl 30-50 m L/min: 250 mg daily; Cr Cl <30 m L/min: 125 mg daily; hemodialysis: 125 mg after dialysis.
For mild hepatic impairment (Child-Pugh class A), no adjustment; for moderate to severe impairment (Child-Pugh class B or C), maximum dose is 20 mg omeprazole once daily due to reduced metabolism.
Child-Pugh A: no adjustment; Child-Pugh B: 250 mg daily; Child-Pugh C: not recommended.
Not established for omeprazole/sodium bicarbonate combination; for omeprazole alone, weight-based dosing: 10-15 mg once daily for weight 10-20 kg, 20 mg once daily for weight >20 kg.
10 mg/kg orally once daily, max 500 mg; for children <2 years: 5 mg/kg once daily.
No specific dose adjustment; use lowest effective dose, monitor for electrolyte imbalance (sodium) and increased risk of Clostridium difficile infection.
Start at 250 mg daily; monitor renal function and adjust based on Cr Cl.
No FDA black box warning.
None
Gastric malignancy: Short-term treatment does not preclude presence of gastric malignancy.,Clostridioides difficile infection: May increase risk.,Bone fracture: Long-term use may increase risk of osteoporosis-related fractures of the hip, wrist, or spine.,Hypomagnesemia: May cause low serum magnesium with prolonged use.,Cyanocobalamin (Vitamin B12) deficiency: Prolonged acid suppression may impair absorption.,Acute interstitial nephritis: Has been observed.,Cutaneous lupus erythematosus: May increase risk.,Interaction with methotrexate: May increase methotrexate toxicity.,Sodium content: Contains sodium bicarbonate; caution in patients on sodium-restricted diet.,Metabolic alkalosis: High doses of bicarbonate may cause metabolic alkalosis.
Acute gout flares may occur initially,Hypersensitivity reactions including Stevens-Johnson syndrome,Renal impairment requires dose adjustment
Hypersensitivity to omeprazole or sodium bicarbonate,Hypersensitivity to other proton pump inhibitors,Concurrent use of rilpivirine,Severe hypokalemia or metabolic alkalosis (due to bicarbonate component)
Hypersensitivity to probalan,Concurrent use with azathioprine or mercaptopurine
Avoid taking with food or within 30 minutes of eating. High-fat meals may delay absorption. No specific food restrictions, but alcohol and spicy foods may exacerbate symptoms.
High-purine foods (organ meats, anchovies, sardines) may increase uric acid; limit intake. Alcohol, especially beer, reduces uricosuric effect and increases uric acid; avoid or limit. Aspirin (anti-inflammatory doses) and some diuretics (thiazides) can reduce efficacy; avoid concurrent use.
First trimester: No increased risk of major congenital malformations based on large cohort studies. Second and third trimesters: Limited data, but no evidence of fetal harm. Omeprazole is FDA Pregnancy Category C; sodium bicarbonate is not associated with teratogenicity.
PROBALAN (probenecid) is not associated with major congenital malformations in human studies. However, dose-dependent neonatal toxicity (lactic acidosis) has been reported with third-trimester exposure due to inhibition of fetal renal clearance. Risk cannot be excluded; use only if maternal benefit outweighs potential fetal risk.
Omeprazole is excreted into breast milk with an M/P ratio of approximately 0.1-0.2. Sodium bicarbonate is also excreted. At therapeutic doses, amounts are unlikely to affect the infant. Manufacturer advises caution, but use is generally considered compatible with breastfeeding.
Probenecid is excreted into breast milk in small amounts. M/P ratio is approximately 0.1. Infant exposure is negligible, but caution is advised due to potential for kernicterus in jaundiced infants. Consider discontinuing breastfeeding if infant is G6PD deficient.
Pregnancy does not significantly alter omeprazole pharmacokinetics. No dose adjustment required, but use lowest effective dose due to limited safety data. Sodium bicarbonate dose may need adjustment if renal impairment or preeclampsia is present.
No standard dose adjustment recommended. Pregnancy increases renal clearance and volume of distribution, potentially reducing serum concentrations. Consider therapeutic drug monitoring if response inadequate. Avoid use in third trimester unless benefits outweigh risks.
Administer on an empty stomach 1 hour before a meal for maximal acid suppression. The sodium bicarbonate component provides rapid antacid effect and may cause belching or gastric distension. Avoid in patients with Bartter's syndrome, hypokalemia, or metabolic alkalosis. Monitor magnesium levels with prolonged use; hypomagnesemia can occur with PPIs. For patients unable to swallow capsules, the contents can be mixed with applesauce.
PROBALAN (probenecid) is a uricosuric agent used for chronic gout. Monitor serum uric acid levels; goal <6 mg/d L. Avoid in patients with creatinine clearance <50 m L/min or history of uric acid stones. Ensure adequate hydration (≥2 L/day) to prevent nephrolithiasis. Alkalinize urine (p H 6.5-7.0) with potassium citrate if needed. Contraindicated with aspirin >1 g/day due to decreased uricosuric effect. Not effective during acute gout attacks; initiate after inflammation subsides.
Take this medication 1 hour before a meal, usually once daily.,Swallow the capsule whole; do not crush or chew. If you have trouble swallowing, open the capsule and mix the granules with a tablespoon of applesauce, then swallow immediately.,Do not take with other antacids unless directed by your doctor.,Inform your doctor if you experience severe diarrhea, muscle cramps, irregular heartbeat, or signs of low magnesium (seizures, dizziness, abnormal heart rhythm).,Long-term use may increase risk of bone fractures, vitamin B12 deficiency, and kidney problems.
Take with food or milk to reduce gastrointestinal upset.,Drink at least 2 liters of water daily to prevent kidney stones.,Avoid aspirin or aspirin-containing products; use acetaminophen for pain.,Report rash, fever, or painful urination immediately.,May take several months to achieve full effect; do not stop suddenly.
"Niclosamide may inhibit the cytochrome P450 enzyme CYP2C19, which is the primary hepatic enzyme responsible for the metabolism of omeprazole. This inhibition can lead to decreased clearance and elevated plasma concentrations of omeprazole, potentially increasing its therapeutic and adverse effects. Clinically, this could result in enhanced acid suppression and an increased risk of omeprazole-related side effects such as headache, diarrhea, or vitamin B12 deficiency with prolonged use."
"Cyclosporine, a potent immunosuppressant and P-glycoprotein inhibitor, can significantly increase the systemic exposure of omeprazole by inhibiting its efflux transport and potentially its metabolism via CYP3A4 and CYP2C19. This interaction may lead to elevated omeprazole serum concentrations, increasing the risk of adverse effects such as headache, diarrhea, and vitamin B12 deficiency with long-term use. Clinicians should be vigilant for signs of omeprazole toxicity when coadministered with cyclosporine."
"Omeprazole, a proton pump inhibitor (PPI), is primarily metabolized by cytochrome P450 (CYP)2C19 and, to a lesser extent, CYP3A4. Stiripentol, an antiepileptic drug, is a potent inhibitor of CYP2C19 and CYP3A4. Coadministration may lead to a significant increase in omeprazole exposure (AUC up to 5-fold), potentially increasing the risk of adverse effects such as hypomagnesemia, Clostridioides difficile infection, or bone fracture. Conversely, stiripentol levels are not expected to be significantly affected, as omeprazole does not inhibit its metabolism."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OMEPRAZOLE AND SODIUM BICARBONATE vs PROBALAN, answered by our medical review team.
OMEPRAZOLE AND SODIUM BICARBONATE is a Alkalinizing Agent that works by Omeprazole is a proton pump inhibitor that suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells. Sodium bicarbonate is an antacid that neutralizes gastric acid.. PROBALAN is a Uricosuric Agent that works by Inhibits xanthine oxidase, reducing uric acid production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OMEPRAZOLE AND SODIUM BICARBONATE and PROBALAN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OMEPRAZOLE AND SODIUM BICARBONATE is: Omeprazole 20 mg plus sodium bicarbonate 1100 mg orally once daily before a meal; for gastroesophageal reflux disease, dose may be increased to 40 mg orally once daily for 4-8 weeks.. The standard adult dose of PROBALAN is: 500 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OMEPRAZOLE AND SODIUM BICARBONATE and PROBALAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OMEPRAZOLE AND SODIUM BICARBONATE is classified as Category A/B. First trimester: No increased risk of major congenital malformations based on large cohort studies. Second and third trimesters: Limited data, but no evidence of fetal harm. Omepra. PROBALAN is classified as Category C. PROBALAN (probenecid) is not associated with major congenital malformations in human studies. However, dose-dependent neonatal toxicity (lactic acidosis) has been reported with thi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.